Targeting MHC-I Molecules for Cancer: Function, Mechanism, and Therapeutic Prospects

Overview

Journal Mol Cancer

Publisher Biomed Central

Specialties Molecular Biology
Oncology

Date 2023 Dec 1

PMID 38041084

Authors

Xiangyu Wu

Tianhang Li

Rui Jiang

Xin Yang

Hongqian Guo

Rong Yang

Affiliations

Soon will be listed here.

Abstract

The molecules of Major histocompatibility class I (MHC-I) load peptides and present them on the cell surface, which provided the immune system with the signal to detect and eliminate the infected or cancerous cells. In the context of cancer, owing to the crucial immune-regulatory roles played by MHC-I molecules, the abnormal modulation of MHC-I expression and function could be hijacked by tumor cells to escape the immune surveillance and attack, thereby promoting tumoral progression and impairing the efficacy of cancer immunotherapy. Here we reviewed and discussed the recent studies and discoveries related to the MHC-I molecules and their multidirectional functions in the development of cancer, mainly focusing on the interactions between MHC-I and the multiple participators in the tumor microenvironment and highlighting the significance of targeting MHC-I for optimizing the efficacy of cancer immunotherapy and a deeper understanding of the dynamic nature and functioning mechanism of MHC-I in cancer.

Citing Articles

A pan-cancer analysis reveals the oncogenic and immunological role of insulin-like growth factor 2 mRNA-binding protein family members.

Zeng F, Chen L, Li J, Yu W, Sa N, Zhang K Discov Oncol. 2025; 16(1):323.

PMID: 40088376 DOI: 10.1007/s12672-025-02077-2.

MHC-I upregulation by macbecin II in the solid tumors potentiates the effect of active immunotherapy.

Deshpande R, Wu K, Wu S, Tyagi A, Smith E, Kim J EMBO Mol Med. 2025; .

PMID: 40087501 DOI: 10.1038/s44321-025-00213-7.

LPIN3 promotes colorectal cancer growth by dampening intratumoral CD8 T cell effector function.

Zhang X, Fang H, Wu W, Jiang C, Wang H, Shi Y Cancer Immunol Immunother. 2025; 74(4):135.

PMID: 40042548 PMC: 11883066. DOI: 10.1007/s00262-025-03989-2.

Tetrandrine augments melanoma cell immunogenicity via dual inhibition of autophagic flux and proteasomal activity enhancing MHC-I presentation.

He L, Liu Y, Jiang J, Wang D, Li Y, Zeng S Acta Pharmacol Sin. 2025; .

PMID: 40016522 DOI: 10.1038/s41401-025-01507-9.

Towards the Prediction of Responses to Cancer Immunotherapy: A Multi-Omics Review.

Tao W, Sun Q, Xu B, Wang R Life (Basel). 2025; 15(2).

PMID: 40003691 PMC: 11856636. DOI: 10.3390/life15020283.

References

Koopman L, Corver W, van der Slik A, Giphart M, Fleuren G . Multiple genetic alterations cause frequent and heterogeneous human histocompatibility leukocyte antigen class I loss in cervical cancer. J Exp Med. 2000; 191(6):961-76. PMC: 2193119. DOI: 10.1084/jem.191.6.961. View

Simoni Y, Becht E, Fehlings M, Loh C, Koo S, Teng K . Bystander CD8 T cells are abundant and phenotypically distinct in human tumour infiltrates. Nature. 2018; 557(7706):575-579. DOI: 10.1038/s41586-018-0130-2. View

Souri Z, Jochemsen A, Versluis M, Wierenga A, Nemati F, van der Velden P . HDAC Inhibition Increases HLA Class I Expression in Uveal Melanoma. Cancers (Basel). 2020; 12(12). PMC: 7763827. DOI: 10.3390/cancers12123690. View

Ye Q, Shen Y, Wang X, Yang J, Miao F, Shen C . Hypermethylation of HLA class I gene is associated with HLA class I down-regulation in human gastric cancer. Tissue Antigens. 2009; 75(1):30-9. DOI: 10.1111/j.1399-0039.2009.01390.x. View

Zebertavage L, Alice A, Crittenden M, Gough M . Transcriptional Upregulation of NLRC5 by Radiation Drives STING- and Interferon-Independent MHC-I Expression on Cancer Cells and T Cell Cytotoxicity. Sci Rep. 2020; 10(1):7376. PMC: 7193601. DOI: 10.1038/s41598-020-64408-3. View

Wang X, Waschke B, Woolaver R, Chen S, Chen Z, Wang J . MHC class I-independent activation of virtual memory CD8 T cells induced by chemotherapeutic agent-treated cancer cells. Cell Mol Immunol. 2020; 18(3):723-734. PMC: 8027191. DOI: 10.1038/s41423-020-0463-2. View

Liu L, Mayes P, Eastman S, Shi H, Yadavilli S, Zhang T . The BRAF and MEK Inhibitors Dabrafenib and Trametinib: Effects on Immune Function and in Combination with Immunomodulatory Antibodies Targeting PD-1, PD-L1, and CTLA-4. Clin Cancer Res. 2015; 21(7):1639-51. DOI: 10.1158/1078-0432.CCR-14-2339. View

Liu X, Song J, Zhang H, Liu X, Zuo F, Zhao Y . Immune checkpoint HLA-E:CD94-NKG2A mediates evasion of circulating tumor cells from NK cell surveillance. Cancer Cell. 2023; 41(2):272-287.e9. DOI: 10.1016/j.ccell.2023.01.001. View

Burr M, Sparbier C, Chan K, Chan Y, Kersbergen A, Lam E . An Evolutionarily Conserved Function of Polycomb Silences the MHC Class I Antigen Presentation Pathway and Enables Immune Evasion in Cancer. Cancer Cell. 2019; 36(4):385-401.e8. PMC: 6876280. DOI: 10.1016/j.ccell.2019.08.008. View

10.

DeSelm C, Palomba M, Yahalom J, Hamieh M, Eyquem J, Rajasekhar V . Low-Dose Radiation Conditioning Enables CAR T Cells to Mitigate Antigen Escape. Mol Ther. 2018; 26(11):2542-2552. PMC: 6225039. DOI: 10.1016/j.ymthe.2018.09.008. View

11.

Jongsma M, de Waard A, Raaben M, Zhang T, Cabukusta B, Platzer R . The SPPL3-Defined Glycosphingolipid Repertoire Orchestrates HLA Class I-Mediated Immune Responses. Immunity. 2020; 54(1):132-150.e9. PMC: 8722104. DOI: 10.1016/j.immuni.2020.11.003. View

12.

Michelakos T, Kontos F, Kurokawa T, Cai L, Sadagopan A, Krijgsman D . Differential role of HLA-A and HLA-B, C expression levels as prognostic markers in colon and rectal cancer. J Immunother Cancer. 2022; 10(3). PMC: 8919449. DOI: 10.1136/jitc-2021-004115. View

13.

McGranahan N, Rosenthal R, Hiley C, Rowan A, Watkins T, Wilson G . Allele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution. Cell. 2017; 171(6):1259-1271.e11. PMC: 5720478. DOI: 10.1016/j.cell.2017.10.001. View

14.

Schaue D, McBride W . Opportunities and challenges of radiotherapy for treating cancer. Nat Rev Clin Oncol. 2015; 12(9):527-40. PMC: 8396062. DOI: 10.1038/nrclinonc.2015.120. View

15.

Gettinger S, Choi J, Hastings K, Truini A, Datar I, Sowell R . Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer. Cancer Discov. 2017; 7(12):1420-1435. PMC: 5718941. DOI: 10.1158/2159-8290.CD-17-0593. View

16.

Hasim A, Abudula M, Aimiduo R, Ma J, Jiao Z, Akula G . Post-transcriptional and epigenetic regulation of antigen processing machinery (APM) components and HLA-I in cervical cancers from Uighur women. PLoS One. 2012; 7(9):e44952. PMC: 3443204. DOI: 10.1371/journal.pone.0044952. View

17.

Blees A, Januliene D, Hofmann T, Koller N, Schmidt C, Trowitzsch S . Structure of the human MHC-I peptide-loading complex. Nature. 2017; 551(7681):525-528. DOI: 10.1038/nature24627. View

18.

Wong-Benito V, de Rijke J, Dixon B . Antigen presentation in vertebrates: Structural and functional aspects. Dev Comp Immunol. 2023; 144:104702. DOI: 10.1016/j.dci.2023.104702. View

19.

Rock K, Reits E, Neefjes J . Present Yourself! By MHC Class I and MHC Class II Molecules. Trends Immunol. 2016; 37(11):724-737. PMC: 5159193. DOI: 10.1016/j.it.2016.08.010. View

20.

Kiselyov A, Bunimovich-Mendrazitsky S, Startsev V . Treatment of non-muscle invasive bladder cancer with Bacillus Calmette-Guerin (BCG): Biological markers and simulation studies. BBA Clin. 2015; 4:27-34. PMC: 4661599. DOI: 10.1016/j.bbacli.2015.06.002. View